Quantum Biopharma (QNTM) Gains from Investment Securities (2019 - 2025)

Quantum Biopharma has reported Gains from Investment Securities for 7 years, with the latest figure at -$12.1 million in Q4 2025.

• Quarterly Gains from Investment Securities fell 38760.91% year-over-year to -$12.1 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was -$618720.0 (down 232.54% YoY) and the FY2025 annual result came in at -$175194.0, changed N/A from the prior year.
• Gains from Investment Securities declined to -$12.1 million in Q4 2025 per QNTM's latest filing, from $1.3 million in the prior quarter.
• Over five years, Gains from Investment Securities peaked at $10.2 million in Q2 2025 and troughed at -$12.1 million in Q4 2025.
• A 5-year average of $45875.8 and a median of $19647.5 in 2023 frame the typical range for Gains from Investment Securities.
• The widest YoY moves for Gains from Investment Securities: up 1690813.51% in 2025, down 38760.91% in 2025.
• Over 5 years, Gains from Investment Securities stood at $839376.0 in 2021, then sank by 117.0% to -$142696.0 in 2022, then surged by 179.34% to $113211.0 in 2023, then tumbled by 72.39% to $31263.0 in 2024, then slumped by 38760.91% to -$12.1 million in 2025.
• According to Business Quant data, Gains from Investment Securities over the past three periods registered -$12.1 million, $1.3 million, and $10.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.